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Objective: Previous studies suggest a positive impact of telehealth in the care of people with 
motor neurone disease/amyotrophic lateral sclerosis (MND/ALS). This study reports the 
development of self-reported questions for telemonitoring, using a tablet-based device 
Careportal®, in the care of patients with MND on non-invasive ventilation (NIV) and its initial 
impact.  
Methods: The study consisted of a question development phase and an evaluation phase of 
the use of Careportal®. The development phase employed a modified Delphi process. The 
evaluation phase involved a 24-week pilot study with 13 patients (median age=66; median 
illness duration=14m), who were using NIV. The participants completed overnight oximetry 
and self-report questions via Careportal® each week, generating interventions where 
required. Patient-ventilator interaction data were monitored and the revised ALS Functional 
Rating Scale (ALSFRS-R) was completed.  
Results: Telemonitoring encompassing the newly developed 26-item symptom questions 
showed good feasibility and validity. During the evaluation phase, 61 interventions were 
made for 10 patients, including seven patients who had routine clinic appointments during 
the trial to optimise care. ALSFRS-R showed significant illness deteriorations. Blood oxygen 
saturation (SpO2) levels were maintained, time ventilated and inspiratory pressures 
increased during the trial. 
Conclusion: The MND OptNIVent question set together with weekly ventilator and oximetry 
monitoring facilitated the maintenance of ventilation and SpO2 levels despite illness 
progression. The use of the question set, and devices such as Careportal®, facilitate care and 
may further enable a single point of contact for patients from which clinicians may offer 
proactive interventions to optimise care. 
 


















Current UK National Institute for Health and Care Excellence (NICE) guidance recommends 
tailored care for people with motor neurone disease/ amyotrophic lateral sclerosis 
(MND/ALS)[1], with a single point of contact, flexible support, and regular monitoring.  
Telemedicine may be used to assist diagnosis, symptom monitoring and management; 
telemonitoring allows the collection of physiological data from a patient. “Telemedicine” 
may be used as an umbrella term for all electronic technologies for communications and 
information exchange for the delivery of healthcare services [2]. However, the term is used 
by some to refer to services delivered by physicians only, whereas “telehealth” is used to 
refer to services provided by wider healthcare professionals [3]. Acknowledging the variety 
of definitions of telemedicine, the World Health Organization (WHO) suggested that 
telemedicine is broadly: “The delivery of health care services, where distance is a critical 
factor, by all health care professionals using information and communication technologies 
for the exchange of valid information for diagnosis, treatment and prevention of disease and 
injuries, research and evaluation, and for the continuing education of health care providers, 
all in the interests of advancing the health of individuals and their communities” [3]. 
Although limited in number, studies of telehealth for the MND population suggest it is 
beneficial. A retrospective study examining the efficacy of telemonitoring found equivalent 
quality of care between the conventional in-person consultation and video-consultation with 
no significant difference in survival time between the groups [4]. A single-arm study of 
phone call follow-up of MND patients by a nurse appeared to have enabled prompt 
intervention, leading Vitacca et al. to suggest the usefulness of using an interview schedule 
for symptom monitoring, which could effectively manage both service time and costs [5,6]. 
The authors suggested weekly telephone calls afforded access to healthcare services that 
was cost effective in managing clinical exacerbations and related respiratory problems 
leading to the proposal that telehealth was a valid approach [7]. However, this study had no 
control arm. A study of weekly remote monitoring of non-invasive ventilation (NIV) 
compliance suggested that telemonitoring serves to reduce hospital utilisation and lower 
care costs when compared with a control arm [8,9]. This study found a trend to longer 
survival among patients using telemonitoring when compared with controls [8], it however, 
did not randomise the study arms, and respiratory function between the telemonitoring 
group and controls was significantly different at baseline, therefore the findings should be 
interpreted with caution.  
These studies point to benefits in utilising telehealth to care for people with MND, however 
randomised controlled trials with adequately powered sample sizes are needed to 
determine the true effect of telehealth in the care of ALS/MND patients [10]. Further 
optimisation of care for MND NIV users may be possible through combining remote follow 
up – as in the nurse-led telephone study – and telemonitoring of NIV compliance and 
efficacy. We envisaged that data from a self-report symptom question set together with the 
measurement of oximetry and patient ventilator interaction would enable clinicians to 
remotely monitor patients and provide interventions in a timely manner. Such an approach 
adds the possibility of more frequent high-quality assessment, which would not necessitate 
travel, resulting in less effort for the patient, and greater efficiency for the clinician. Given 
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the potential benefits of monitoring symptoms and NIV compliance [5,6,8,9], we 
investigated how combining both types of information further impacts upon the care of 
MND patients on NIV using a remote monitoring device, CAREPORTAL® (Figure 1). Using 
web-based clinical database, Careportal® offers a central contact point, as recommended by 
NICE, facilitating working between different multidisciplinary teams, community and 
hospital. The device is a tablet style computer encased in an integrated cradle to facilitate 
user friendliness and connection to peripherals such as a pulse oximeter; data is transferred 
from the patient to a N3 (National Health Service secure) cloud and a base station such as a 
personal computer. 
[Figure 1 about here] 
We designed a study that utilised a bespoke question set to assess respiratory-related 
symptom changes and NIV related issues, combined with oximetry and patient ventilation 
interaction data. The investigative study was planned with a view of establishing a 
telemonitoring service through a call centre operated by the local Clinical Commissioning 
Group (CCG). The objectives were two-fold: firstly to develop bespoke questions for 
Careportal®, and then to evaluate the use of the questions as a function of telemonitoring in 
the care of MND NIV users. In this report, we describe the development and initial 
evaluation of telemonitoring using the bespoke questions in terms of work generated for the 
clinical team. A qualitative evaluation of the impact on patients and caregiver was 
undertaken and will be reported separately.  
Methods  
The study was conducted at Aintree University Hospital National Health Service (NHS) 
Foundation Trust (AUHFT) in North-West England, UK. The Ventilation Inpatient Centre at 
the trust care for individuals with MND, who have symptoms and or evidence of respiratory 
impairment. NICE guidance is followed in the management of these patients. Please refer to 
Supplementary file (Suppl. 1) for the description of usual care provided at the study site. 
Ethical concerns 
Potential participants were given a participant information sheet and written consent was 
obtained after participants had a chance to ask any questions. The study received favourable 
responses by the local Ethics Committee and by Research and Development department at 
the study site (14/WA/1199). 
Participants 
Opportunity sampling was used for recruitment. Potential participants were identified by the 
clinical care team from the MND NIV user database held at the Ventilation Inpatient Centre 
at the study site. Inclusion criteria for recruitment were: confirmed diagnosis of MND with 
respiratory muscle weakness; compliant with NIV (i.e. using NIV ≥4 hours per night); capable 
of informed consent; anticipated survival time of ≥6 months. See Figure 2 for the 
recruitment process.  
 
[Figure 2 about here] 
Study Design 
The study involved two phases: the development of bespoke questions for Careportal®, and 
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the evaluation of the use of the questions via Careportal® in the care of MND NIV users. 
 
Phase 1: bespoke questions development 
This phase involved initial question set development and subsequent evaluation of its 
feasibility and validity. As illustrated in Figure 3, a modified Delphi [11] approach was 
undertaken. The expert panels comprised clinicians and researchers with at least 2 years’ 
experience of supporting people with MND. The questions featured notification system to 
assist clinicians with symptom monitoring for timely care (see Table 1 for details). Due to the 
word limit, the details of this phase are provided as supplementary data (Suppl. 2).  
[Figure 3 about here] 
[Table 1 about here] 
Phase 2: evaluation of the use of telemonitoring  
The final question set (MND OptNIVent; See Supple. 3) from Phase 1 was trialled for 24 
weeks to evaluate its use for telemonitoring, including face validity and feasibility of this 
approach.  
18 patients were identified as meeting the recruitment criteria of whom 14 patients 
consented to enrol into the study. All participants from the development phase were invited 
to participate in the validation phase except one, who had died before the start of Phase 2, 
resulting in the total of 13 participants. During this phase, participants were prompted to 
answer questions and transfer nocturnal pulse oximetry readings once a week via 
Careportal®. An integrated messaging system on Careportal® allowed participants to contact 
the clinical team any time. All participants received education in terms of symptoms 
suggestive of chest infections and on respiratory management; they were advised to contact 
their general practitioner (GP) for emergencies. All were provided with rescue antibiotics. 
Feasibility and validity of questions through Careportal® 
Weekly follow-up was conducted via the messaging system to identify notification failures. 
Feasibility was tested by assessing the average completion rate; an overall response rate 
greater than 80% was predetermined to indicate good feasibility.  
Data collection 
Demographics, illness characteristics, and information on existing routine clinic 
appointments were collected from medical notes for each participant, and baseline 
pulmonary function testing was performed at the study site.  
In order to evaluate how remote monitoring affects patient-ventilator interaction (PVI) 
maintenance, participants posted the secure digital (SD) card located in the ventilator 
(Respironics BiPAP Trilogy100) weekly during the study period. Participants were asked to 
use NIV initially at night during sleep with a minimum of 4 hours nightly. A self-report NIV 




All data were transmitted to the study site and were monitored the next working day after 
participants entered the data by a non-clinical researcher, who notified a respiratory 
physiotherapist for further assessment on the same day if any signs of worsening of the 
condition were acknowledged through high priority notifications. Queries raised by 
participants via the messaging system were also communicated with the physiotherapist. No 
clinical judgement was made by the non-clinical researcher. The physiotherapist was 
required to respond to acute respiratory events defined as: multiple new high priority 
notifications for one week; one high priority notification for two consecutive weeks; 
suboptimal nocturnal blood oxygen saturation (SpO2) levels for two consecutive weeks. In 
this study, suboptimal SpO2 was defined as: mean SpO2 <90%, time spent under 90% SpO2 
overnight ≥20 minutes, and/or dips in SpO2 per hour ≥5. The researcher and physiotherapist 
also had open access to both respiratory physicians involved in the study, and if they were 
not available, then the respiratory consultant on call would be available for advice for the 
ventilation patients.  
Measurement 
Physical functioning of participants in daily activities was measured using the revised ALS 
Functional Rating Scale (ALSFRS-R) [12,13] at three points: baseline, Week 12 and Week 24. 
Given previous concern that it is a multidimensional scale [14], sub-scores of the three 
domains are also reported: bulbar (Item 1-3); motor (Item 4-9); respiratory (Item 10-12). 
Each item is scored from 0 to 4 with higher scores indicating better function.  
Data Analysis 
Numbers of alerts, follow-up interventions, and any contacts initiated by patients were 
recorded during the study. Descriptive analyses were conducted for the number of alerts 
and interventions. Timing of interventions was also assessed in relation to routine clinic 
appointments to evaluate how Careportal® may contribute to optimising care. 
All weekly data were analysed using data from three points: baseline, Week 12 and Week 24. 
Any significant findings from 12-weekly assessment were then followed by 4-weekly 
evaluations and weekly analyses where appropriate. Given the small sample size with great 
variance of the baseline clinical characteristics, assessing medians using non-parametric 
tests was appropriate. Differences between time points were examined using Friedman’s 
ANOVA and Wilcoxon signed-rank tests. Bonferroni corrections were applied where 
appropriate. Correlations were tested using Spearman’s correlation coefficient. Exact 
significance p-value was used where available due to the small sample size [15]. A p-value 
of .05 was considered significant.  
Results 
13 participants consented. Table 2 reports baseline characteristics of the participants. Table 
3 shows median values for each variable at baseline, 12 and 24 weeks. 
[Table 2 about here] 
[Table 3 about here] 
Feasibility and validity of questions through Careportal® 
There were no notification failures in the weekly follow-up. Ten patients had 100% 
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completion rate for the questions while they were in the study, the other three completed at 
least 80% of the required sessions. 
Illness trajectory 
Total ALSFRS-R scores changed significantly over the whole trial: 𝑋"(2) = 8.19, 𝑝	 = .01. 
Wilcoxon tests were used to follow up this finding (see Table 4). When the three domains of 
ALSFRS-R were assessed separately, significant change was observed only with bulbar 
domain:	𝑋"(2) = 7.27, 𝑝	 < .05. The following Wilcoxon tests showed better bulbar 
function at the baseline when compared with the end point, 𝑧 = −2.27, 𝑟 = −.53, 𝑝	 < .05.  
[Table 4 about here] 
SpO2, NIV adherence, and patient-NIV interaction data 
88.2% of the required assessments for SpO2 were completed by participants. The range of 
the completion rate per participant was 66.7% to 100% (median = 91.7%). The average time 
of the recording time for overnight SpO2 was 6h 40m (median = 6h 56m) with a range of 3h 
36m to 8h per participant. Over the study period, no change was observed with nocturnal 
pulse oximetry in terms of average SpO2 levels, time spent <90%, or rate of 4% dip.  
NIV usage was assessed 12-weekly and it changed significantly over time: 𝑋"(2) =
10.46, 𝑝 = .003. See Table 4 for Wilcoxon tests. Both 4-weekly assessment and weekly 
assessment also showed a significant change over time: 𝑋"(6) = 28.85, 𝑝 < .001 and 
𝑋"(23) = 44.39, 𝑝 = .005, respectively.  
Availability of PVI data varied between participants with a range from 0% (n=2) to 100% 
(n=1). The two participants with no PVI data withdrew from NIV or died; the technical team 
deleted the memory before it was retrieved. The median rate for availability was 87.5 
(IQR=14.85). The availability of the data for Week 23 and Week 24 was particularly poor; 
60% and 50%, respectively. Consequently, data analysis on PVI data was assessed from Week 
1 to Week 22 only. Due to the omission of Week 23 and Week 24, assessment was tested up 
to Week 22 and data for three points were taken from Week 1 (n=11), Week 12 (n=10) and 
Week 22 (n=9). 
When changes between baseline, Week 12, and Week 22 were assessed, the only significant 
difference was found with IPAP levels: 𝑋"(2) = 8.86, 𝑝	 = .008.	Wilcoxon tests were 
performed and presented in Table 4. 
High priority notifications 
136 high priority notifications were made during the trial with a mean of 5.7 notifications 
per week (range from 2 to 10). See Figure 4 for the distribution of the notifications. A total 
number of high priority notifications triggered per participant during the trial ranged from 0 
to 29 (Median = 8). 
 
[Figure 4 about here] 
 
During the trial, average SpO2 levels for eight participants fell under 90%; nine participants 





In total, 61 interventions (Median = 5) were made during the trial for ten (77%) participants 
in response to telemonitoring (see Table 5 for intervention category). Amongst the ten 
participants, the number of interventions varied from two to nine.  
[Table 5 about here] 
Of these interventions, seven (i.e. 58% of provision of NIV accessories) were requested by 
the participants via message system or telephone (circumventing the usual email system). 
Six interventions resulted from suboptimal overnight oximetry readings leading to five NIV 
adjustments for two participants. Elective admission was made for three participants, two to 
optimise chest clearance and ventilation and one for optimisation of ventilation; one had 
been brought to clinic but due the complexity of the interventions needed admission was 
offered and accepted. 
Interventions and healthcare utilisation 
Three participants (23%) were not assessed in routine clinic during the trial yet needed 
intervention. Seven (54%) had routine clinic appointments during the trial; telemonitoring 
for six of these participants triggered 19 interventions: NIV adjustment (n=6); new 
home/outpatient review (n=5); providing accessories for NIV (n=4); cough insufflator 
adjustment (n=2); providing second ventilator for NIV (n=1); new hospital appointment 
(n=1). 
During the study, five participants reported taking antibiotics for chest or sinus infections on 
11 occasions. Three patients made unplanned GP contacts and one of them was hospitalised 
with pneumonia, despite being on antibiotics. This patient admission was not identified via 
Careportal® as symptoms developed between Careportal® entries. Another patient utilised 
accident and emergency (A&E) services one week after declining the new inpatient 
appointment offered by the physiotherapist following consecutive high priority notifications 
and suboptimal SpO2 levels. This participant withdrew from the study following the 
admission to A&E. 
Illness trajectories and telemonitoring 
One of the two deceased participants made the last entry the day before their death, 
triggering three high priority notifications. Previously, there had been no high priority 
notifications triggered by this participant; at the time they were receiving antibiotics from 
their GP for a respiratory tract infection. Another participant who was felt to be “pre-
terminal” triggered two high priority notifications as their last entry, leading the 
physiotherapist to arrange a home visit with a view to reviewing interventions; the visit was 
for two weeks later but the patient died before the visit. 
Amongst the 10 survivors, no correlations were found between the total number of 
interventions and total ALSFRS-R scores or any three sub-scores of ALSFRS-R. Number of 
interventions was significantly negatively related with illness duration: 𝑟8(10) = −.74, 𝑝 =
.014 and NIV duration, 𝑟8(10) = −.69, 𝑝 = .028.  
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Impact of telemonitoring on clinical team 
Twelve (19.7%) of the 61 interventions were to arrange a new appointments i.e. clinical 
review. Three of the 12 appointments arranged were subsequently cancelled by patients; 
the resulting nine face-to-face contacts initiated 31.1% of all interventions made during the 
trial. 16.4% of interventions were phone calls to request advice from other professionals; 
11.5% of interventions (i.e. seven treatment adjustments) took place during existing hospital 
visits since these visits fell within a reasonable timescale for response to alerts; 21.3% of 
interventions were equipment dispatch.  
Discussion 
This study reports the development of a 26-item self-report MND OptNIVent question set for 
weekly remote monitoring of individuals with MND on NIV. The development of the 
questions allowed formatting for telemonitoring. The potential benefit of regular monitoring 
of general MND symptoms through self-report questions has been recently suggested by 
Hobson et al. [16]. In the current study, we demonstrated a self-question set with a focus on 
the respiratory management to have face validity and good feasibility.  
The evaluation phase showed weekly telemonitoring through the Careportal® to be effective 
in prompting changes allowing optimisation of the ventilatory support of patients with MND 
on NIV, in terms of SpO2 levels and ventilation. In particular, ten of the thirteen participants 
seemed to benefit from close symptom monitoring and received interventions to optimise 
their care outside their existing hospital appointments. Only six interventions were triggered 
solely by suboptimal overnight oximetry readings, highlighting the importance of symptom 
review in addition to physiological data. This work demonstrates that the symptom related 
questions communicated here via Careportal® enabled clinicians to remotely monitor 
patient’s symptoms effectively and provided a means to offer timely and appropriate 
support or intervention. Furthermore, participants utilised the message system to 
communicate their needs, suggesting the importance of combining all the aspects to 
optimise care for this patient group.  
More than two-thirds of participants required interventions before and after existing routine 
appointments, suggesting telemonitoring has the potential to replace some traditional 
reviews and link the patient more effectively to their care team. The combination of 
education, availability of rescue antibiotics plus telemonitoring allowed effective 
management of intercurrent illnesses. Interestingly, one participant was admitted within 
days of declining the offer of an admission for adjustment of management again suggesting 
that the telemonitoring service was effective in identifying their deterioration to clinicians. 
The perceived effectiveness of care through telehealth resulting from frequent contacts with 
patients has been reported among patients with differing conditions [17-19]. Such continual 
monitoring may be particularly beneficial in optimising care in patients with MND on NIV 
given that there were many interventions required. Of note, during this time, there were no 
significant changes in the respiratory domain sub-score of ALSFRS-R, possibly reflecting a 
ceiling effect [14] or perhaps the effectiveness of the support. In contrast, the self-report 
questions were found effective in detecting weekly changes of symptoms, enabling clinicians 
to provide timely care.  
Although 61 interventions were generated through telemonitoring, most interventions were 
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completed via telephone calls with only nine face-to-face reviews taking place over the trial 
period. It was also noted that when a home visit was undertaken in response to issues 
highlighted, as the clinician had access to the patient’s equipment, multiple interventions 
could take place at one time, which may otherwise have required several outpatient 
attendances. While a comprehensive assessment of the impact of telehealth on health 
economics needs to be undertaken, these observations suggest the approach is likely to be 
feasible economically. 
The current study found the total number of interventions to be negatively related with 
illness duration and NIV usage time; the longer a patient had MND or NIV, the less they 
needed interventions. Although this seems to contradict the general understanding of this 
degenerative illness, its course is known to vary [20]. In particular, the current study included 
three individuals who displayed slower progression (i.e. > 30 months from onset at the 
baseline). Only two interventions were prompted during the trial for one of these three 
patients, whilst the other two required no intervention. The findings suggest this patient 
subgroup require less input from clinicians perhaps due to their stable conditions or to well-
implemented support systems over years. Telehealth such as Careportal® appears to benefit 
this patient subgroup by providing an effective communication method while also allowing 
monitoring against sign of deterioration for which an intervention may be needed.  
It is interesting to consider that telemonitoring may particularly benefit those in the final 
stage of the disease when rapid deterioration may occur [21]. A telehealth service is 
anticipated to facilitate home-based care, which is desired by many patients towards the 
end of life [22], but not met in most cases in England [23]. The observation that two 
participants triggered multiple high priority notifications shortly before their death suggests 
communicating using the Careportal® remains viable in the terminal phase in a home 
environment. This type of link facilitating timely access to care should benefit not only the 
patient, but also their family, who often act as primary caregivers.  
 
Limitations of the study 
This question set focuses on respiratory-related symptoms as the population in question was 
MND patients using NIV therapy, although a question on adequacy of care, two on 
swallowing and the availability of the anytime message system meant that other key issues 
could be raised. Further question development could reflect patients’ complex needs, and 
be tailored to patients’ as suggested by Hobson et al. [16] to feed into MDT management for 
the whole ALS/MND population.  
The current study involved a small sample size. While it is clear that the questions work and 
alerts are appropriate, further evaluation with a bigger cohort should be undertaken with 
the MND OptNIVent question set to determine its utility in real life, including its sensitivity 
and the range of multiple-choice options for answers. Ideally this would be in a randomised 
trial assessing telehealth against routine care. 
While PVI data was available through posting, it hindered timely monitoring of NIV 
compliance. The loss of data particularly at Week 23 and Week 24 also confirms the 
importance of remote transmission of PVI data; this is now available. The benefits of such 





We have developed a brief self-reported assessment comprised of a question set together 
with triggered alerts to monitor respiratory related symptoms and NIV related issues 
commonly experienced amongst ventilated patients with MND. Currently, 3-monthly review 
is recommended by NICE guidelines for people with MND. This work showed that 61.5% of 
patients in the study needed more frequent review, while 23.1% did not require any 
intervention in the 24-week period. Telemonitoring using the Careportal® device or a similar 
system integrating the MND OptNIVent question set, oximetry and PVI may allow a tailored 
approach to patient care, enhancing the current model of follow-up through improved 
patient-clinician communication.  
A system like Careportal® could provide the single point of contact allowing signposting to 
the right member of the care team as communications are received. This may lead to more 
timely interventions where needed and reduce hospital appointments as they would not be 
required. It is envisaged that some routine clinic reviews could therefore be replaced by tele-
clinics with the data gathered from the proactive monitoring offering a comprehensive basis 
for a consultation. We now plan to translate this work to a routine practice setting in 
collaboration with one of local commissioning groups which is an early adopter of telehealth 
and has a call centre which can monitor the patients. This can link to the NIV and MND 
specialist services and also to the primary care teams via data sharing (Figure 5).  
[Figure 5 about here] 
We also suggest that a multicentre randomised controlled trial to evaluate the effect of 
telemonitoring in the care of people with MND who are on NIV should be undertaken. This 
should include the role of telemonitoring in acute deteriorations, a health economic 
evaluation with a cost optimisation assessment, comparison of key health outcomes and 
patient preference comparing traditional clinic reviews with proactive telehealth.  
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